Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 4/20 | 0.51 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.51 |
| ▸ | MMP1 | P03956 | 1/20 | 0.51 |
| ▸ | MMP3 | P08254 | 1/20 | 0.51 |
| ▸ | MMP9 | P14780 | 1/20 | 0.51 |
| ▸ | MMP12 | P39900 | 1/20 | 0.51 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL353673 | 0.85 | EPHX2 (0.44) | ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL353339 | 0.85 | EPHX2 (0.44) | ALDH1A1LMNASMN1; SMN2 | |
| SCHEMBL354323 | 0.84 | RPS6KB1 (0.42) | CYP2D6KCNH2MMP1MMP3MMP9 | |
| SCHEMBL6009898 | 0.82 | HTT (0.43) | CYP2D6MEN1KMT2AALDH1A1PKM | |
| SCHEMBL6009893 | 0.82 | HTT (0.43) | CYP2D6MEN1KMT2AALDH1A1PKM | |
| SCHEMBL6009922 | 0.82 | HTT (0.43) | CYP2D6MEN1KMT2AALDH1A1PKM | |
| SCHEMBL354864 | 0.75 | MTNR1A (0.44) | — | |
| SCHEMBL353209 | 0.74 | SIGMAR1 (0.47) | — | |
| SCHEMBL5503364 | 0.74 | CA2 (0.40) | MEN1KMT2AALDH1A1PKMLMNA | |
| SCHEMBL10278392 | 0.74 | CYP2D6 (0.33) | CYP2D6KCNH2MMP1MMP3MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060183800-A1 | Methods and fluorinated compositions for treating amyloid-related diseases | BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) | 2006-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060183800-A1 | Methods and fluorinated compositions for treating amyloid-related diseases | APP, PSEN1, TTR | CYP2D6 2171/4885KCNH2 2375/4885MMP1 1446/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.